Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
ASH 2011 Annual Meeting
Economic Burden of Febrile Neutropenia in NHL Exceeds $11,000 per Episode
By
Caroline Helwick
ASH Highlights
,
ASH 2011 Annual Meeting
March 2012, Vol 3, No 2
San Diego, CA—Among patients with non-Hodgkin lymphoma (NHL), costs related to febrile neutropenia (FN) treated with hospitalization exceed $11,000 per episode, researchers reported at ASH 2011.
Read Article
Long-Term Survivors of Hematopoietic Stem-Cell Transplant Pose Significant Burden to Healthcare System
By
Phoebe Starr
ASH Highlights
,
ASH 2011 Annual Meeting
March 2012, Vol 3, No 2
San Diego, CA—Survivors of hematopoietic cell transplant (HCT) have substantial medical illnesses and psychological symptoms ≥10 years after the procedure, representing a substantial burden to our healthcare system.
Read Article
Novel Oral B-Cell Receptor Inhibitor Very Effective in Chronic Lymphocytic Leukemia
By
Caroline Helwick
ASH Highlights
,
ASH 2011 Annual Meeting
March 2012, Vol 3, No 2
San Diego, CA—A novel inhibitor of B-cell receptor signaling, PCI-32765, produced high rates of remission and was well tolerated in patients with chronic lymphocytic leukemia (CLL) whose disease was refractory to at least 2 previous treatments, reported Susan O'Brien, MD, of the University of Texas M.D. Anderson Cancer Center, Houston.
Read Article
Lymphoma Treatment in Pregnancy Does Not Compromise Fetal/Maternal Outcomes
ASH Highlights
,
ASH 2011 Annual Meeting
March 2012, Vol 3, No 2
San Diego, CA—The treatment of lymphoma during pregnancy does not compromise fetal outcomes or maternal health and cancer-specific survival, according to a study presented at ASH 2011 from the University of Massachusetts Medical School in Worcester.
Read Article
Chemotherapy Superior to Radiation for Nonbulky Hodgkin Lymphoma, but Older Radiotherapy Method Was Evaluated
ASH Highlights
,
ASH 2011 Annual Meeting
March 2012, Vol 3, No 2
In patients with early-stage, nonbulky Hodgkin lymphoma (HL), overall survival (OS) was superior at 12 years in patients who received standard chemotherapy compared with radiotherapy in a study conducted by the National Cancer Institute of Canada's Clinical Trials Group and the Eastern Cooperative Oncology Group.
Read Article
Confusion Still Surrounds Prophylaxis for Venous Thromboembolism
By
Caroline Helwick
ASH Highlights
,
ASH 2011 Annual Meeting
March 2012, Vol 3, No 2
San Diego, CA—Venous thromboembolism (VTE) occurs in 1% of hematologic malignancies and can lead to fatal pulmonary emboli, postthrombotic syndromes, bleeding as a result of anticoagulant treatment, and recurrent VTE.
Read Article
High-Risk Myelodysplastic Syndrome: First-Line Treatment Choices Often Not Supported by Evidence
By
Caroline Helwick
ASH Highlights
,
ASH 2011 Annual Meeting
March 2012, Vol 3, No 2
A review of treatment patterns for higher-risk myelodysplastic syndrome (MDS) shows growing use of lenalidomide, despite the lack of phase 3 survival data supporting this approach, according to research conducted at the Mayo Clinic Florida, Jacksonville, in collaboration with Xcenda, a research and consulting firm.
Read Article
Cryoprecipate Is Overused, an Unnecessary Expense
ASH Highlights
,
ASH 2011 Annual Meeting
March 2012, Vol 3, No 2
San Diego, CA—Only 30% of cryoprecipitate was used in accordance with established guidelines in a tertiary care center, in a study presented at ASH 2011 by researchers from Beth Israel Medical Center, Newark, NJ.
Read Article
VTE Prophylaxis during Chemotherapy Cost-Effective
By
Caroline Helwick
ASH Highlights
,
ASH 2011 Annual Meeting
February 2012, Vol 3, No 1
Venous thromboembolism (VTE) is a common cause of serious morbidity and mortality, and patients with cancer are at particular risk. “VTE has a substantial burden on the current US medical system.
Read Article
First Randomized Comparison of Catheter-Directed Thrombolysis versus Standard Care for DVT Prophylaxis
By
Neil Canavan
ASH Highlights
,
ASH 2011 Annual Meeting
February 2012, Vol 3, No 1
In the first comparative trial of its kind, the Catheter-Directed Venous Thrombolysis (CaVenT) study determined that treating a clot directly with the recombinant, antithrombotic agent alteplase reduced the frequency of postthrombotic syndrome (PTS) and improved long-term outcome in patients with proximal deep-vein thrombosis (DVT) compared with standard anticoagulation methods.
Read Article
Page 1 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma